RhumbLine Advisers’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

RhumbLine Advisers’s Portfolio TARO Stock Details TARO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-12,625	Closed	-$542K	–	4408
2024 Q2	$542K	Buy	12,625 +3,018	+31%	+$128K	﹤0.01%	2619
2024 Q1	$407K	Buy	9,607 +257	+3%	+$10.8K	﹤0.01%	2792
2023 Q4	$391K	Sell	9,350 -406	-4%	-$15K	﹤0.01%	2814
2023 Q3	$368K	Buy	9,756 +419	+4%	+$15.7K	﹤0.01%	2808
2023 Q2	$354K	Buy	+9,337	New	+$293K	﹤0.01%	2903

Other funds holding TARO

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

RhumbLine Advisers's TARO Position: Q3 2024 in Review

RhumbLine Advisers sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q3 2024, closing a stake of 12,625 shares — an estimated $542K sold.

RhumbLine Advisers first reported a position in TARO in Q2 2023 and held it in 5 quarters. The position peaked at $542K in Q2 2024. 6 funds tracked by Wall St. Rank hold TARO as of Q3 2024.

RhumbLine Advisers reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q3 2024 after selling out during the quarter.
RhumbLine Advisers sold 12,625 Taro Pharmaceutical Industries Ltd. shares in Q3 2024, an estimated $542K.
RhumbLine Advisers first reported a position in Taro Pharmaceutical Industries Ltd. in Q2 2023 and held it in 5 quarters.
RhumbLine Advisers's Taro Pharmaceutical Industries Ltd. position peaked at $542K in Q2 2024.
6 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.